phrykt

Calidi Biotherapeutics, Inc. (CLDI): who owns it and who trades it

As of Nov 16, 2026, CLDI insiders reported 1 open-market sale worth $1.2K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Allan Camaisa (Director), with $1.2K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Calidi Biotherapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, CLDI insiders reported $0 of open-market purchases and $1.2K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$1.2K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Dec 12, 2025
Filed Dec 16, 2025

Purchases and sales by month

$1.2K$1.2KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 12, 2025Allan CamaisaDirectorSale850$1.46$1.2KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Allan CamaisaDirector–$1.2KDec 12, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CLDI short interest

Moderate short interest. 5.3% of CLDI shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went down 80%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 135,691 CLDI shares were sold short, 5.3% of the shares outstanding, down 17.4% from the report before. At the average daily volume of 54,754 shares, buying them all back would take about 2.5 trading days (days to cover).

Shares short, % of all shares

5.25%May 15Oct 3044.8%

Days to cover

2.5May 15Oct 307.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026135,6915.25%-17%54,7542.5
Oct 15, 2026164,2956.36%-30%39,2274.2
Sep 30, 2026233,2879.03%+2%380,1011.0
Sep 15, 2026227,7758.81%-1%36,5726.2
Aug 31, 2026231,1178.94%-26%98,1002.4
Aug 14, 2026313,26112.12%+35%201,5761.6
Jul 31, 2026231,3182.12%-93%665,8881.0
Jul 15, 20263.42M31.40%-20%2.13M1.6
Jun 30, 20264.28M39.24%+251%6.27M1.0
Jun 15, 20261.22M11.17%+64%4.88M1.0
May 29, 2026743,9226.83%+11%2.30M1.0
May 15, 2026670,6146.15%-78%2.41M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Calidi Biotherapeutics company events

Calidi Biotherapeutics filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Sep 25, 2026.

  1. Sep 25, 2026ListingCalidi Biotherapeutics, Inc. received a letter from staff of NYSE American LLC. Filing
  2. Sep 22, 2026AgreementCalidi Biotherapeutics, Inc. entered into a stock purchase agreement with certain accredited investors and/or qualified institutional buyers named therein, pursuant to which the Company agreed to issue and sell directly to the Purchasers, in a registered direct offering, an aggregate of 1,025,640… Filing
  3. Aug 13, 2026ResultsReleased financial results. Filing
  4. Jul 31, 2026SharesChanged the rights of its shareholders. Filing
  5. Jul 16, 2026AgreementCalidi Biotherapeutics, Inc. entered into a lease agreement with BP3-SD4 5580 Morehouse Drive LLC, a Delaware limited liability company, pursuant to which the Company will lease approximately 9,038 rentable square feet of office and laboratory space located in Suite 120 at 5580 Morehouse Drive, San… Filing
  6. Jun 23, 2026LeadershipThe Board of Directors of Calidi Biotherapeutics, Inc., upon the recommendation of the Nominating and Corporate Governance Committee appointed Dr. Corazon (Corsee) Sanders to serve as a Class III director of the Company, with a term expiring at the Company’s 2029 annual meeting of stockholders and… Filing
  7. Jun 18, 2026VoteReported shareholder vote results. Filing
  8. May 29, 2026AgreementEntry into Material Definitive Agreement The information under Item 3.02 below is incorporated herein by reference. Filing
  9. May 14, 2026ResultsReleased financial results. Filing
  10. May 8, 2026AgreementEntry into Material Definitive Agreement The information under Item 3.02 below is incorporated herein by reference. Filing
  11. Apr 2, 2026LeadershipMr. Allan J. Camaisa, a member of the Board of Directors of Calidi Biotherapeutics, Inc., informed the Nominating and Corporate Governance Committee of the Board that, he intends to allow the term of his Director position on the Board to expire, which expiration date is scheduled to be the date of… Filing
  12. Mar 27, 2026ResultsReleased financial results. Filing
  13. Mar 11, 2026AgreementCalidi Biotherapeutics, Inc. entered into an underwriting agreement with Ladenburg Thalmann & Co. Inc., as sole underwriter, in connection with the issuance and sale of: (i) 2,278,731 common stock units, which includes 1,575,000 Common Stock Units purchased pursuant to the exercise, in full, of the… Filing
  14. Feb 10, 2026AnnouncementShared information with investors. Filing
  15. Jan 29, 2026AnnouncementThe Company issued a press release providing corporate updates for the fiscal year ended December 31, 2025, and updates on key operational initiatives for fiscal year 2026, which also includes certain preliminary, unaudited financial information. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Calidi Biotherapeutics financials

Famous investors that hold CLDI

1 of the 50 well-known investors we track reported holding CLDI in their latest 13F filing. The largest position is Ken Griffin's, worth $90.4K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202684,441$90.4K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Calidi Biotherapeutics, Inc. (CLDI) stock

Are CLDI insiders buying or selling?

In the last 12 months, CLDI insiders reported no open-market purchases and 1 sale worth $1.2K. The latest trade was on Dec 12, 2025. See every trade.

What is the short interest in CLDI?

As of Oct 30, 2026, 135,691 CLDI shares were sold short, 5.3% of the shares outstanding, down 17.4% from the report before. At the average daily volume of 54,754 shares, buying them all back would take about 2.5 trading days (days to cover). See the history.

Which famous investors hold CLDI?

1 of the 50 well-known investors we track reported CLDI in their latest 13F filing, including Ken Griffin. The largest position is worth $90.4K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.